Nocturnal enuresis (NE) in school-age children is more than a nighttime inconvenience: when persistent, it can affect self-esteem, sleep, family life and social functioning. An updated expert consensus now offers a practical roadmap for recognizing and treating childhood NE, with 18 recommendations spanning diagnosis, classification, evaluation, first-line therapy, comorbidity management and referral. The framework lowers the diagnostic frequency threshold to at least one involuntary nighttime void per month for three months in children aged five years or older, and places greater emphasis on tailoring treatment to the child's clinical pattern. The goal is to help clinicians move from symptom-based treatment toward more standardized, individualized and family-centered care.
Nocturnal enuresis (NE) is common in childhood and arises from multiple interacting factors, including excess nighttime urine production, reduced functional bladder capacity and difficulty waking to bladder signals. Effective treatments are available, yet underdiagnosis, inconsistent clinical practice and poor adherence continue to limit outcomes. In China, care is further complicated by regional differences in access, cultural perceptions of bedwetting and uneven coordination between primary and specialist services. Since the previous Chinese consensus was issued in 2014, international standards and the evidence base have changed substantially, while domestic clinical experience has expanded. Given these challenges, an updated, locally applicable framework was needed to align diagnosis, treatment and referral with current evidence and frontline practice.
Researchers from the Department of Nephrology, Children's Hospital of Fudan University, National Children's Medical Center, together with the Chinese Cooperative Group for the Management of Pediatric NE and the Pediatric Nephrology Committee of the Chinese Medical Doctor Association, published (DOI: 10.1007/s12519-026-01051-4) an updated expert guidance in the World Journal of Pediatrics . The consensus establishes 18 recommendations for diagnosing, classifying, and managing childhood NE, emphasizing symptom-based classification, voiding diaries, individualized first-line treatment, management of daytime urinary symptoms and comorbidities, and referral pathways for refractory cases.
The consensus introduces several key updates. First, it lowers the diagnostic threshold: children aged five years or older who experience at least one involuntary nighttime void per month for three months now qualify for diagnosis—a shift from the previous weekly standard that enables earlier intervention. Second, it mandates a clear clinical distinction between monosymptomatic NE (MNE), without daytime lower urinary tract symptoms (LUTS), and non‑monosymptomatic NE (NMNE), where daytime symptoms such as urgency, frequency or incontinence are present. This classification drives all subsequent treatment decisions. Third, the voiding diary becomes a diagnostic cornerstone—patients must record at least two daytime charts and seven consecutive nights of fluid intake and voids, allowing clinicians to phenotype children as having nocturnal polyuria, reduced bladder capacity, or both. For MNE, the consensus specifies phenotype‑driven first‑line therapy: desmopressin for nocturnal polyuria and the enuresis alarm for reduced bladder capacity, with combination therapy for mixed types. For NMNE, management must prioritize daytime LUTS and comorbidities—especially constipation, which affects 36–80% of these children—before addressing nighttime wetting. The framework also outlines clear referral criteria: primary care may manage MNE, but non‑responders or suspected NMNE require specialist evaluation with urodynamics and lumbosacral magnetic resonance imaging (MRI). For refractory cases, defined as less than 50% improvement after three months, the consensus advises systematic re‑evaluation of adherence, diary findings and underlying causes before escalating treatment.
The authors said the central message is that NE should not be managed as a single, uniform disorder. They said the updated pathway asks clinicians to identify the child's specific pattern, look for daytime symptoms and comorbidities, and match treatment to the likely underlying mechanism while keeping the family involved. They also stressed that apparent treatment failure should trigger a careful review—of adherence, voiding records and possible missed conditions—before stronger or more complex therapy is added. In this way, they said, the consensus is designed to make care both more systematic and more responsive to individual children.
In practice, the recommendations could help pediatricians and primary‑care clinicians identify children who can be managed locally and those who need specialist assessment. Clearer use of voiding diaries and symptom‑based classification may reduce trial‑and‑error treatment, while earlier attention to constipation, sleep‑disordered breathing, attention‑deficit/hyperactivity disorder (ADHD) and daytime urinary symptoms could improve response rates. The framework also encourages timely referral when first‑line therapy fails or NMNE is suspected, supporting better coordination across levels of care. The authors acknowledge that some recommendations reflect Chinese practice patterns and that evidence remains limited for areas such as desmopressin withdrawal strategies. Future trials and multidisciplinary care models could further refine individualized treatment.
